Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial

• Main Authors: Brett King (Author), Emma Guttman-Yassky (Author), Elena Peeva (Author), Anindita Banerjee (Author), Linda Zhu (Author), Hua Zhu (Author), Lori Ann Cox (Author), Michael S. Vincent (Author), Rodney Sinclair (Author)
• Format: Book
• Published: Elsevier, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The 24-week, double-blind period of the ALLEGRO phase 2a trial (NCT02974868) evaluated the safety and efficacy of ritlecitinib (Jak3/tyrosine kinase expressed in the hepatocellular carcinoma inhibitor) and brepocitinib (tyrosine kinase 2/Jak1 inhibitor) in patients with alopecia areata; patients cou...